<?xml version="1.0" encoding="UTF-8"?>
<p>As the majority of the patients in the NEPA pivotal trials were Caucasian, this study raises the question as to whether similar antiemetic efficacy would be seen in Asian and Caucasian populations. Additional studies would be needed to determine this; however, it is reassuring that a comparison of the pharmacokinetic profiles of netupitant and palonosetron in Chinese and Caucasian patients show differences considered as not clinically meaningful [
 <xref rid="mdx698-B23" ref-type="bibr">23</xref>].
</p>
